AndHealth Plus

Macuject has been selected as a recipient of the highly competitive AndHealth+ award for 2022.

Five digital health companies will benefit from in $5m in funding to accelerate commercialisation of their platforms.

The funding will be used to generate real-world evidence, finalise commercial models, advance regulatory approval and progress toward commercial launch.

For more information, please visit the following page:

https://www.andhealth.com.au/news/22-5m-digital-health-accelerator-announces-second-cohort

‍